Interferon-α2b might prolong life and save costs in HBeAg-positive chronic hepatitis B

EconomicsNovember 1, 1995Interferon-α2b might prolong life and save costs in HBeAg-positive chronic hepatitis BRonald L. Koretz, MDRonald L. Koretz, MDUniversity of California at Los Angeles Medical School Sylmar, California, USA (R.L.K.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-1995-123-3-085 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookTwitterLinkedInRedditEmail Source CitationWong JB, Koff RS, Tinè F, Pauker SG. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1995 May 1;122:664-75.Reference1 Koretz RL. Chronic hepatitis: more quotes and misquotes. In: Gitnick GL, ed. Current Hepatology. Volume 15. Chicago: Mosby-Year Book; 1995:49-84. Google Scholar Author, Article, and Disclosure InformationAffiliations: University of California at Los Angeles Medical School Sylmar, California, USA (R.L.K.) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails November 1, 1995Volume 123, Issue 3Page: 85KeywordsAminotransferasesAntigensBiomarkersChronic hepatitisChronic hepatitis BCirrhosisClinical trialsHepatitisHepatitis BHepatocellular carcinomaInfectious hepatitisInterferonsLife expectancyLiver diseasesMorbidity ePublished: 9 March 2020 Issue Published: November 1, 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.Loading ...